Telix Pharmaceuticals announces results of successful SPP
Filed with ASX · · 2 pages · English
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Telix and GenesisCare Commence Prostate Cancer Study
- Telix and Merck Group Combination Therapy Collaboration
- Sales Note to Accompany June 2019 Quarter Appendix 4C
- Appendix 4C - June 2019 Quarter
- Telix Receives $9.3m R&D Tax Refund
Later from Telix Pharmaceuticals
- First Australian Patient Dosed in ZIRCON Phase III Trial
- Appendix 4D and Financial Report for half-year to 30 June 19
- FDA Pre-NDA Meeting Outcomes - TLX591-CDx illumet
- Telix to Acquire European Production Facility
- Appendix 4C - September 2019 quarter
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals